BetaPublic beta

Spending
Lobbying
Coming soon: Congress, Stocks

Spending
- Overview
- Agencies
- Programs
- Recipients
- Awards
Lobbying
Congress
Stocks

About Privacy Terms

© 2026 Adaptrex, LLC

About
Privacy
Terms

© 2026 Adaptrex, LLC

Spending
Lobbying
Coming soon: Congress, Stocks

Overview Firms Clients Revolving Door Stands Out

IPSEN BIOPHARMACEUTICALS, INC. — Lobbying — Receipts Report

LD-2 disclosure · 3rd Quarter - Report

IPSEN BIOPHARMACEUTICALS, INC.

via W STRATEGIES, LLC

3rd Quarter (July 1 - Sep 30) · 2025Posted Oct 20, 2025Filing document ↗LDA record ↗

Income$20Kfee reported

Client

Name: IPSEN BIOPHARMACEUTICALS, INC.
Description: Biopharmaceutical company.
Location: New Jersey · United States of America

Registrant

Firm: W STRATEGIES, LLC
Description: Government Affairs Consulting Firm.
Location: Washington, District of Columbia, United States of America

Lobbying activities

1 issue

Medicare/Medicaid
Monitored Public Law 119-21: One Big Beautiful Bill Act.
LobbyistsDARREN WILLCOX

Source

Source · Senate Office of Public Records — Lobbying Disclosure Act filings ↗.

Coverage gaps · LD-2 reports a single dollar figure per quarter on ONE basis — income (a fee) or expenses (self-filed spend), never both — so this page never combines them into one "spend" number.